Company profile: AB Science
1.1 - Company Overview
Company description
- Provider of pharmaceutical therapies specializing in tyrosine kinase inhibitors, including Masitinib being developed for ALS, indolent systemic mastocytosis, severe asthma, progressive MS, first-line pancreatic cancer with pain, Alzheimer’s disease, and metastatic castrate-resistant prostate cancer, and AB8939, a microtubule destabilizer being developed for acute myeloid leukemia.
Products and services
- AB8939: New-generation microtubule destabilizer being developed for the treatment of Acute Myeloid Leukemia, engineered as an anti-microtubule product for AML therapy
- Masitinib: Highly selective tyrosine kinase inhibitor being developed for ALS, indolent systemic mastocytosis, severe asthma, progressive multiple sclerosis, first‑line pancreatic cancer with pain, Alzheimer’s disease, and metastatic castrate‑resistant prostate cancer
- Tyrosine kinase inhibitor drug discovery and development: Mechanism-targeted pharmaceutical R&D that discovers key life-science mechanisms and develops new drugs addressing the most unmet medical needs
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to AB Science
NMS Group
HQ: Italy
Website
- Description: Provider of oncology research and development, managing the integrated R&D chain from pre-clinical to clinical stages. Operates a validated oncology drug discovery platform generating a pipeline of new chemical entities (NCEs).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NMS Group company profile →
Intera Oncology
HQ: United States
Website
- Description: Provider of hepatic artery infusion (HAI) therapy and liver-directed chemotherapy delivery for colorectal cancer and cholangiocarcinoma patients, offering the Intera 3000 HAI pump, Cerona Therapeutics Floxuridine for Injection, USP, and related products (heparinized saline, saline, bacteriostatic water); acquired Oncology/Neuromodulation Drug Delivery products from Johnson & Johnson.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intera Oncology company profile →
Lengo Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical solutions focused on discovering and developing cancer treatments, including AYVAKIT/AYVAKYT (avapritinib) for systemic mastocytosis and gastrointestinal stromal tumors with PDGFRA exon 18 mutations. Offers clinical trials, a U.S. patient support program for access and affordability, and a scientific platform to develop highly selective medicines for mast cell disorders and cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lengo Therapeutics company profile →
Immunis AI
HQ: United States
Website
- Description: Provider of non-invasive, blood-based Active Surveillance Tests for active surveillance and early detection of diseases, initially validated for prostate cancer with future applications in other urological cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunis AI company profile →
Theriva Biologics
HQ: United States
Website
- Description: Provider of biologics for the prevention and treatment of serious infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theriva Biologics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for AB Science
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to AB Science
2.2 - Growth funds investing in similar companies to AB Science
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for AB Science
4.2 - Public trading comparable groups for AB Science
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →